SCHEMBL6133440

SCHEMBL6133440

O=C(OCc1ccccc1)c1ccc(F)cc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.58
HTT P42858 1/20 0.57
ALDH1A1 P00352 2/20 0.53
TDP1 Q9NUW8 3/20 0.51
KDM4E B2RXH2 3/20 0.51
PTGER1 P34995 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 2/20 0.50
NPC1 O15118 1/20 0.50
MEN1 O00255 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 1/20 0.50
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31371501 1.00 FFAR4 (0.58) FFAR4HTTALDH1A1TDP1KDM4E
SCHEMBL1646547 0.89 HTT (0.57) HTTALDH1A1TDP1KDM4EL3MBTL1
SCHEMBL23182973 0.87 KMT2A (0.55) FFAR4HTTALDH1A1TDP1KDM4E
SCHEMBL1958139 0.87 FFAR4 (0.75) FFAR4HTTPTGER1L3MBTL1LMNA
SCHEMBL28911191 0.87 MCL1 (0.56) FFAR4TDP1PTGER1L3MBTL1LMNA
SCHEMBL31336015 0.85 MAOB (0.58) HTTALDH1A1TDP1L3MBTL1KMT2A
SCHEMBL3189637 0.85 TDP1 (0.58) HTTALDH1A1TDP1L3MBTL1KMT2A
SCHEMBL4943007 0.85 MAOB (0.58) HTTALDH1A1TDP1L3MBTL1KMT2A
SCHEMBL4415350 0.85 HTT (0.75) HTTALDH1A1TDP1PTGER1L3MBTL1
SCHEMBL23809724 0.85 ALDH1A1 (0.62) HTTALDH1A1TDP1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025034849-A1 FUSED PYRIDAZINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2025-02-13 WO disclosed
US-6908940-B2 Imidazole compounds and their use as adenosine deaminase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-21 US disclosed
US-20040097571-A1 Imidazole compounds and their use as adenosine deaminase inhibitors ASTELLAS PHARMA INC. (JP) 2004-05-20 US disclosed
EP-1261589-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-04 EP disclosed
WO-2001053271-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097571-A1 Imidazole compounds and their use as adenosine deaminase inhibitors ADA, AMPD2, AMPD1 FFAR4 3599/4885HTT 3158/4885ALDH1A1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.